table of contents - heart failurelaheartfailure.com/support/heartfailure2019_syllabus.pdf ·...

TABLE OF CONTENTS

Acknowledgements ............................................................................................................3Course Information ..........................................................................................................4 Description, Program Objectives, Target AudienceAccreditation Information ................................................................................................4 Needs Assessment, Accreditation Statement, Faculty Disclosure Statement, Cultural and Linguistic Competency Statement, HFSAFaculty List ........................................................................................................................7Faculty Disclosures ............................................................................................................8Program ............................................................................................................................10Faculty Bios Program Director Uri Elkayam, MD, FACC ..............................................................................................11 Program Co-Director Anil K. Bhandari, MD, FACC, FHRS ..........................................................................12 Invited Faculty William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCP ..................................13 Eric Adler, MD, FACC ..................................................................................................14 Inder Anand, MD, PhD ..................................................................................................15 David Cannom, MD, FACC, FHRS ..............................................................................16 Maria Rosa Costanzo, MD ............................................................................................17 Barry H. Greenberg, MD, FACC ..................................................................................18 Yehuda Handelsman, MD ..............................................................................................19 Munir S. Janmohamed, MD, FACC ..............................................................................20 Alan Maisel, MD, FACC................................................................................................21 Mathew S. Maurer, MD ................................................................................................22 Tien M.H. Ng, PharmD, FHFSA, FCCP, BCPS AQ Cardiology ..................................23 Prediman K. Shah, MD, FACC......................................................................................24 Nir Uriel, MD, MSc ......................................................................................................25

23rd Annual Heart Failure 2019

An Update on TherapySaturday, April 13, 2019 Millennium Biltmore Hotel Los Angeles, CA

2

ACKNOWLEDGEMENTS

We would like to acknowledge the following companies andorganizations for their support of this symposium.

JanssenNovartis

•

AstraZeneca, Inc.Good Samaritan Hospital

Pfizer •

AbbottAbiomed

Actelion PharmaceuticalsAlnylamRelypsa

•

Akcea Therapeutics

Amgen

Biosense Webster

Boston Scientific

California Chapter of the American College of Cardiology

Medtronic

Zoll LifeVest



3

COURSE DESCRIPTIONThis year’s program provides a comprehensive update on the prevention, diagnosis and management ofheart failure (HF). The program includes lectures presented by experts combined with interactive discus-sion with faculty. The extensive list of topics has been selected to provide a high level, contemporary andclinically relevant update with a goal of improving the care of patients with heart failure.

PROGRAM OBJECTIVESAt the conclusion of this activity, the participants should be able to:1. Implement effective therapy for lipid disorders2. Manage diabetes in patients with HF3. Use new FDA approved drugs for the treatment of chronic HF4. Identify new therapeutic approaches for patients with chronic HF including iron replacement5. Apply effective management of the hospitalized patients with HF6. Understand the clinical implications and management strategies of worsening kidney function

during treatment of HF7. Assess and follow patients with HF using devices for remote hemodynamic monitoring8. Manage patients with pulmonary arterial hypertension9. Understand new information on atrial fibrillation ablation in patients with HF10. Utilize new biomarkers for the diagnosis and management of patients with HF11. Understand mechanisms, diagnosis and management of postural tachycardia syndrome12. Use new therapies for the prevention and treatment of hyponatremia and hyperkalemia13. Review results of recent trials and define indications for percutaneous mitral valve repair in

patients with HF14. Understand the mechanisms and hemodynamic effects of bedside circulatory assist devices for

the management of severe HF and cardiogenic shock15. Identify the new durable mechanical circulatory support as a bridge to transplantation or as

destination therapy16. Provide an update on the management of peripartum cardiomyopathy17. Develop a stepwise approach to early diagnosis and treatment of cardiac amyloidosis18. Integrate guidelines for the use of palliative care for HF patients

TARGET AUDIENCEThis program has been designed to provide cardiologists, internists, primary care physicians, pharma-cists, nurses and other healthcare providers with the necessary information to increase knowledge withthe goal of improving the care of patients with HF.

NEEDS ASSESSMENTeart failure (HF) is common, but often unrecognized and misdiagnosed. It affects over 6 million Americansand is one of few cardiovascular disorders on the rise. An estimated 670,000 new cases are diagnosed eachyear and this condition is a major cause of morbidity and mortality and is the leading cause of hospitalizationsof the elderly in the U.S. The importance of prevention through early identification and better treatment ofrisk factors such as hypertension, diabetes mellitus, obesity and lipid disorders and of education of bothpatients and physicians has been emphasized (Circulation 2013;128:e240)). There is strong evidence that increased use of evidence based, life sustaining therapies and performancemeasures have a significant impact on the outcome of patients with HF ( BMC CV Disorders 2016;16:195)).Recent data continues to show that life-saving drug and devices are underutilized (Eur Heart J 2009; 30:2493,Circulation 2010; 122:585, JACC 2016; 67:1062) indicating the need for education and incorporation ofrecent guidelines by clinicians (Circulation 2017;136: e137).



continued4

The development of biomarkers and imaging modalities has provided clinicians with important tools for diag-nosis and assessment of prognosis. There is however a great need for education regarding an effective use ofthese new diagnostic modalities (Nature Reviews Cardiology 2012; 9:347). HF is the leading cause of hospi-talizations and management of hospitalized patients is complex and challenging (Crit Path Cardiol 2015;14:12). Valvular heart disease is an important cause of HF and effective therapy has been underutilized (AnnThorac Surg 2010; 90:1904).

Atrial fibrillation (AF) is common in patients with HF and is the leading cause of cardioembolic stroke. Anumber of new agents have been added to the therapeutic options for prevention of thromboembolic compli-cations in patients with AF, yet in spite of their proven efficacy approximately half of eligible patients remainuntreated (JACC 2016; 67:2444).

Pulmonary hypertension (PH) is a major cause of right ventricular failure and an increasing cause of death.Delayed diagnosis and underutilization of effective therapy lead to poor outcome (JACC 2015; 65:1971).

The diagnosis of cardiac amyloidosis is often delayed because the symptoms vary. It is critical to diagnosethis condition early and characterize the various types of the disease which are treated differently. (Curr ProblCardiol 2018;43:10)

Recent data have shown that drugs and devices that have been proven beneficial and are recommended inrecent practice guidelines, are underutilized (JACC 2016; 67:1062), at the same time non-evidence-basedimplantation of expensive devices has been shown to be common (Sana M, et al JAMA 2011; 305:43).Recent introduction of cardiac assist devices provides opportunity for improvement of quality of life and pro-longed survival in patients with advanced HF , inappropriate and delayed referral for this procedure oftenresults in poor outcomes (Eur J Heart Failure 2017;19:595).

Establishing educational initiatives such as this program should help to reduce practice variability, eliminate gapsbetween guidelines and practice and improve the outcome of patients with HF (J Clin Med Res 2014; 6:173).

ACCREDITATION STATEMENTThis Live activity, 23rd Annual Heart Failure 2019: An Update on Therapy , with a beginning date of04/13/2019, has been reviewed and is acceptable for up to 6.5 Prescribed credit(s) by the AmericanAcademy of Family Physicians. Physicians should claim only the credit commensurate with the extent oftheir participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRACategory 1 Credit™ toward the AMA Physician's Recognition Award.

AANP: The American Academy of Nurse Practitioners accepts AAFP Prescribed credit. This program wasplanned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.

ANCC: According to the ANCC, the continuing education hours approved by the AAFP meet the ANCC-accredited CNE criteria.

AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed credit for AAPACategory 1 CME credit.



5

FACULTY DISCLOSURE

It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection,development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflictsof interest will be resolved prior to an educational activity being delivered to learners through one of the followingmechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s controlover CME content about the products or services of the commercial interest, and/or 3) validating the activity contentthrough independent peer review. All persons are also required to disclose any discussions of off label/unapproveduses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity.Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning orpresentation of the activity. This information is used to plan future activities.



HEART FAILURE SOCIETY OF AMERICA

Officially endorsed by the Heart Failure Society of America. The opinions presented in this edu-cational activity do not necessarily reflect the opinions or recommendations of the HFSA.

CULTURAL AND LINGUISTIC COMPETENCY. This activity is in compliance with California Assembly Bill 1195 which requires continuing medical educa-tion activities with patient care components to include curriculum in the subjects of cultural and linguisticcompetency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enableshealth care professionals or organizations to care effectively for patients from diverse cultures, groups, andcommunities. Linguistic competency is defined as the ability of a physician or surgeon to provide patientswho do not speak English or who have limited ability to speak English, direct communication in the patient’sprimary language. Cultural and linguistic competency was incorporated into the planning of this activity.

6



FACULTY

Uri Elkayam, MD, FACCProfessor of MedicineDivision of CardiologyUniversity of Southern CaliforniaLos Angeles, CA

Anil K. Bhandari, MD, FACC, FHRSClinical Professor of MedicineKeck USC MedicineDirector, Electrophysiology ServicesGood Samaritan HospitalDirector, Clinical Cardiac Electrophysiology Fellowship ProgramHarbor UCLA/Good Samaritan HospitalLos Angeles, CA

Program Director Program Co-Director

Guest Faculty

William T. Abraham, MD, FACP, FACC,FAHA, FESC, FRCPProfessor of Medicine, Physiology and Cell BiologyChair of Excellence in Cardiovascular MedicineCollege of Medicine Distinguished ProfessorDirector, Division of Cardiovascular MedicineAssociate Dean for Clinical ResearchDirector, Clinical Trials Management OfficeDeputy Director, Davis Heart & Lung Research InsituteThe Ohio State UniversityColumbus, OH

Eric Adler, MD, FACCProfessor of MedicineMedical Director, Cardiac TransplantHeart Failure and Transplant CardiologyUC San Diego, La Jolla, CA

Inder Anand, MD, FRCP, D Phil (Oxon.)Professor of MedicineUniversity of Minnesota Medical SchoolVA Medical Centers

Minneapolis, MN and San Diego, CA

David Cannom, MD, FACC, FHRSMedical Director of Cardiology, Good Samaritan HospitalDirector of Cardiovascular Trial Development & Engagement,Cedars-Sinai Heart InstituteClinical Professor of Medicine, UCLA School of MedicineLos Angeles, CA

Maria Rosa Costanzo, MDMedical Director, Heart Failure ResearchAdvocate Heart InstituteNaperville, IL

Barry H. Greenberg, MD, FACCDistinguished Professor of MedicineDirector, Advanced Heart Failure Treatment ProgramUC San DiegoLa Jolla, CA

Yehuda Handelsman, MDMedical Director & Principal InvestigatorMetabolic Institute of America Inc.Tarzana, CA

Munir S. Janmohamed, MD, FACCMedical Director, Mechanical Circulatory Support/Heart Failure ProgramMercy General HospitalMercy Medical Group CardiologySacramento, CA

Alan Maisel, MD, FACCEmeritus Professor of CardiologyUC San Diego La Jolla, CA terans Affairs Medical CenterLa Jolla, CA

Mathew S. Maurer, MDArnold and Arlene Goldstein Professor of CardiologyProfessor of MedicineDirector, Clinical Cardiovascular Research Laboratory for the ElderlyColumbia University Irving Medical CenterNew York Presbyterian HospitalNew York, NY

Tien M.H. Ng, PharmD, FHFSA, FCCP,BCPS AQ Cardiology Associate Professor of Clinical Pharmacy and MedicineDirector, PGY2 Residency in CardiologyVice Chair, Titus Family Department of Clinical PharmacySchool of Pharmacy & Keck School of MedicineUniversity of Southern CaliforniaLos Angeles, CA

Prediman K. Shah, MD, FACCShappell and Webb Family Chair in Clinical CardiologyDirector, Oppenheimer Atherosclerosis Research CenterDirector, Atherosclerosis Prevention and Treatment CenterCedars-Sinai Heart InstituteProfessor of Medicine and Cardiology,David Geffen School of Medicine, UCLALos Angeles, CA

Nir Uriel, MD, MScLouis Block Professor of MedicineDirector of Heart Failure, Transplant and Mechanical Circulatory Support Section of CardiologyThe University of Chicago MedicineChicago, IL

7

!

It is the policy of AAFP to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual’s control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose are disqualified from participating in the CME activity. Participants will be asked to evaluate whether the speaker’s outside interests reflect a possible bias in the planning or presentation of the activity. This information is used to plan future activities.

Name Name of Commercial Interest Nature of Relevant Relationship

Employee, Grants/Research Support recipient, Board Member, Advisor or Review Panel member, Consultant, Independent Contractor, Stock Shareholder (excluding

mutual funds), Speakers’ Bureau, Honorarium recipient, Royalty recipient, Holder of Intellectual Property Rights,

or Other William T. Abraham, MD Abbott (Mitraclip, Cardiomems)

Impulse Dynamics V-Wave

Consultant Consultant Consultant

Anil Bhandari, MD Johnson & Johnson St. Jude

Speakers’ Bureau/Consultant Consultant

Maria Rosa Costanzo, MD Abbott CHF – Solution Axon Technologies Fresenius

Consultant/Steering Committee of Guide HF Trial Scientific Advisory Board Consultant Executive Committee of Pure-HF Trial

Uri Elkayam, MD Janssen Astra Zeneca Novartis Abiomed

Speakers’ Bureau Speakers’ Bureau Speakers’ Bureau Consultant

Yehuda Handelsman, MD Amgen Astra Zeneca Bristol Meyer Squibb Boehringer Ingelheim Gan & Lee Hamni Janssen Lexicon Merck Mylan Novo Nordisk Sanofi Aegerion Amarin Gilead Intarcia Lilly Merck-Pfizer Regeneron Target BI-Lilly

Research Grant/Advisory/Consultant/Speakers’ Bureau Research Grant/Advisory/Consultant/Speakers’ Bureau Research Grant Research Grant/Advisory/Consultant Research Grant Research Grant Research Grant/Advisory/Consultant/Speakers’ Bureau Research Grant Research Grant/Advisory/Consultant/Speakers’ Bureau Research Grant Research Grant/Advisory/Consultant/Speakers’ Bureau Research Grant/Advisory/Consultant/Speakers’ Bureau Advisory/Consultant/Speakers’ Bureau Advisory/Consultant/Speakers’ Bureau Advisory/Consultant Advisory/Consultant Advisory/Consultant Advisory/Consultant Speakers’ Bureau/Advisory/Consultant Advisory/Consultant Speakers’ Bureau

Mathew S. Maurer, MD Pfizer, Inc. Alnylam, Inc. Eidos, Inc. Akcea, Inc.

Research/Advisory Boards Advisory Boards Research Grants/Advisory Boards Advisory Boards

Tien Ng, PharmD Otsuka America Pharmaceuticals Research Funding



DISCLOSURES

continued8



DISCLOSUREScontinued

!

Nir Uriel, MD Abbott Medtronic

Consultant Consultant

The following have no relevant financial relationships to disclose: Eric Adler, MD, Inger Singh Anand, MD, David Cannom, MD, Barry Greenberg, MD, Munir S. Janmohamed, MD, Alan Maisel, MD, Prediman K. Shah, MD,

The CME staff, meeting planners, and CME committee reviewers do not have any relevant financial relationships to disclose. This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of AAFP.

9

23rd Annual

Heart Failure 2019An Update on Therapy

Saturday, April 13, 2019 Millennium Biltmore Hotel Los Angeles, CA

PROGRAM

6:30am Registration and Coffee

7:00 Breakfast/Product Theatre (Non-CME) Supported by Janssen Advances in the Management of CAD/PAD: A New Treatment for Thrombotic Risk Reduction Anil Bhandari, MD

8:00 Introduction Uri Elkayam, MD

8:10 Cardio Protection with Novel Anti-diabetic Medications – A Cardiologist’s Perspective Uri Elkayam, MD

8:30 Cardio Protection with Novel Anti-Diabetic Medications – A Endocrinologist’s Perspective Yehuda Handelsman, MD

8:50 The Management of Volume Overload in the Hospitalized Patient with Heart Failure: Drugs and Devices Maria Rosa Costanzo, MD

9:10 Hyponatremia and the Complex Interplay Between Congestion, Kidney Injury and Worsening of Renal Function in the Hospitalized Patient Tien Ng, PharmD

9:30 The Latest in Biomarkers: BNP, ST2 and hsTn - What Must You Know? Alan Maisel, MD

9:50 Coffee Break/Visit Exhibits

10:10 Percutaneous Device Interventions for the Management of Mitral Regurgitation; Results of Trials and Clinical Implications William Abraham, MD

10:30 Postural Tachycardia Syndrome, Mechanism, Diagnosis and Therapy David Cannom, MD

10:50 Bedside Devices for the Management of Cardiogenic Shock: Mechanisms and Hemodynamic Effects Nir Uriel, MD

11:10 Device Technologies to Reduce Heart Failure Readmissions William Abraham, MD

11:30 Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapy Inder Anand, MD

11:50 Update on PCSK9 Inhibition Prediman K. Shah, MD

12:10 Lunch/Product Theatre (non-CME) Supported by Novartis

1:30 Break/Visit Exhibits

1:45 Catheter Ablation for Atrial Fibrillation with Heart Failure – The Implications of the CASTLE-AF Study Anil Bhandari, MD

2:05 LVAD as a Bridge to Transplantation and Destination Therapy: An Update Nir Uriel, MD

2:25 Hyperkalemia and Heart Failure: Clinical Implications and Strategies for Prevention and Management Barry Greenberg, MD

2:45 Stepwise Approach for the Diagnosis of Amyloid Heart Disease Mathew Maurer, MD

3:05 Bromocriptine for the Treatment of Peripartum Cardiomyopathy: Are We There Yet? Uri Elkayam, MD

3:25 Coffee Break/Visit Exhibits

3:45 Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir Janmohamed, MD

4:05 Cardiac Amyloidosis: Emerging Treatment Mathew Maurer, MD

4:25 Palliative Care for Patients with Heart Failure: When and How? Eric Adler, MD

4:45 Program Review and Closing Remarks Uri Elkayam, MD

4:55 Meeting Adjourned

10

Uri Elkayam, MD, FACCProfessor of MedicineDivision of Cardiology

University of Southern CaliforniaLos Angeles, CA

Uri Elkayam, MD received his medical degree from the Tel-Aviv University, Israel, in1973 and is presently Professor of Medicine (Cardiology) at the University ofSouthern California in Los Angeles. He is a past member of the executive counciland chairman of the corporate affairs committee of the American Society of CardiacFailure. Doctor Elkayam is a member of the editorial boards of the AmericanJournal of Cardiology, JACC heart failure, Cardiology, Journal of cardiovascularpharmacology and Therapeutics and Cardiology in Review and a past member ofthe editorial boards of JACC and the Journal of Cardiac Failure. He is a fellow ofthe American College of Cardiology, American Heart Association and AmericanCollege of chest physicians.

Doctor Elkayam’s research and clinical interests are in the areas of congestive heartfailure, heart disease and pregnancy, valvular heart disease, cardiomyopathies andcardiovascular pharmacology. He has been involved in more than 100 self initiated;NIH and industry funded research projects and served in a leading position innumerous national and international multi-center studies. He is the author or co-author on over 190 publications and over 80 book chapters and has the distinctionof being listed in Best Doctors in America and America's Top Doctors from 2001 to2016 and as one of the top 100 most influential Israelis in the U.S. in 2011.



11

Anil K. Bhandari, MD, FACC, FHRSClinical Professor of Medicine

Keck USC MedicineDirector, Electrophysiology Services

Good Samaritan HospitalDirector, Clinical Cardiac Electrophysiology Fellowship Program

Harbor UCLA/Good Samaritan HospitalLos Angeles, CA

Dr. Bhandari completed his cardiology fellowship at the University of Rochester in New York in 1982and electrophysiology training in 1983 at the University of California, San Francisco under the mentor-ship of Melvin Scheinman. This was the era when the field of cardiac electrophysiology ablative pro-cedures was born. While there, Dr. Bhandari worked in the dog lab to learn the fundamentals of abla-tive procedures and, thereafter, performed some of the earliest ablative procedures using direct cur-rent electrical energy at University of California, San Francisco. Thereafter, he joined USC as anAssistant Professor of Medicine where he started a very successful electrophysiology training pro-gram. During his tenure there he published over 50 articles in peer review journals and was promot-ed to Associate Professor of Medicine after 5 years.

Dr. Bhandari joined Los Angeles Cardiology Associates in 1989 where he, along with David Cannom,has been one of the two senior electrophysiology partners. Under their leadership, the electrophysi-ology training program at Good Samaritan Hospital has become a nationally and internationallyknown program. Dr. Bhandari was instrumental in starting radiofrequency ablative procedures atGood Samaritan Hospital and performed one of the first radiofrequency ablative procedures for WolffParkinson White (WPW) and supraventricular tachycardia in Los Angeles.

From the very beginning he nurtured a culture of excellence for the procedure outcome and patientsafety. He self taught himself the technical aspects of cardiac ablative procedures and went on toteach the skills to clinical cardiac electrophysiology fellows over the years. He has been Director ofthe Cardiac Electrophysiology Fellowship Program since 1992 where two fellows are trained eachyear. Over the years this has been a sought after program for fellows looking to be trained inadvanced cardiac electrophysiology.

Dr. Bhandari has a very active tertiary level cardiac electrophysiology practice. Over the last 20 yearshe has performed over 300 complex radiofrequency ablative procedures on a yearly basis. His refer-ral base extends from Los Angeles to Bakersfield to the north, Simi Valley and Oxnard to the west,Orange County to the South, and Palm Springs to the east. He has started and directed the electro-physiology laboratory at San Antonio Community Hospital in Upland and Palmdale Regional MedicalCenter in Lancaster. Both are very successful programs and have continued to grow over the years.

In addition, to his busy and active practice, Dr. Bhandari maintains his academic interests. He contin-ues to publish in the peer review journals and is involved in many basic cardiac electrophysiologyprojects along with Dr. Robert Kloner at Good Samaritan Hospital. He has spoken at many of thenational and international cardiac electrophysiology meetings and has been course director for manyof the regional and national meetings. In addition, he is a member of the editorial board for theJournal of Cardiovascular Pharmacology.

Dr. Bhandari’s passion lies in the field of cardiac ablative procedures and he intends to remaininvolved in the cutting edge technology. He aspires to spearhead the growth of a regional atrial fibril-lation treatment center that will be staffed by some of the best and well known faculty. The facilitywill have state-of-the-art equipment for ablative procedures, should be able to provide comprehensivecare to patients with drug refractory atrial fibrillation. With involvement of a strong hospital partner,this is certainly an achievable goal and he intends to pursue it with vigor.



12

William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPProfessor of Medicine, Physiology and Cell Biology

College of Medicine Distinguished ProfessorDivision of Cardiovascular Medicine

The Ohio State UniversityColumbus, OH

Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts,following which he completed his residency in Internal Medicine and fellowships inCardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University ofColorado Health Sciences Center. He previously held leadership positions at the University ofColorado, the University of Cincinnati, the University of Kentucky, and the Ohio StateUniversity. At Ohio State, Dr. Abraham held several leadership positions including an AssociateDean position, managing the College of Medicine’s non-cancer clinical and translational researchportfolio of more than 1,800 studies. As Division Director at Ohio State, Dr. Abraham developedone of the largest and most successful academic programs of Cardiovascular Medicine in the U.S.

Clinically, Dr. Abraham is board certified in Internal Medicine and Advanced Heart Failure andTransplant Cardiology. He spends the majority of his clinical time managing heart failurepatients in the inpatient and outpatient settings. Dr. Abraham has been recognized as one of the“Best Doctors in America” for sixteen consecutive years and is ranked among the top 10% ofphysicians nationally in patient satisfaction.

Dr. Abraham’s research activities focus on elucidating basic mechanisms in heart failure and onclinical drug and device trials in heart failure. Dr. Abraham has received grants from the NationalInstitutes of Health (NIH) including current NIH funding, the American College of Cardiology,and the Aetna Quality Care Foundation. He has made major contributions to advancing clinicalscience and patient care in heart failure in at least three areas: device development in heart failureand related co-morbidities; neurohormonal therapies in heart failure; and acute heart failure andrenal dysfunction complicating heart failure. Dr. Abraham has participated in all clinical andregulatory phases of new drug and device development from pre-clinical evaluation to Pre-Market Approval (PMA) and New Drug Application (NDA) submission and approval. He hasextensive experience interacting with the U.S. Food and Drug Administration and as a consultantto various CE Marking Notified Bodies of the European Union. His work has led to the approvaland adoption of several new therapies for heart failure, including beta-blockers, natriureticpeptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamicmonitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, andtranscatheter mitral valve repair.

Dr. Abraham has authored more than 1,000 original papers, abstracts, book chapters, and reviewarticles. His work has been published in high impact journals, including The New EnglandJournal of Medicine, The Lancet, the Journal of the American Medical Association, Circulation,the European Heart Journal, and the Journal of the American College of Cardiology. Dr.Abraham has co-authored national heart failure practice guidelines and co-edited a leadingtextbook on heart failure entitled Heart Failure: A Practical Approach to Treatment and serves asseries editor for the Color Atlas and Synopsis of Cardiovascular Medicine. Dr. Abraham serveson the editorial boards of several major journals. Annually since 2014, he was named to theClarivate Analytics (formerly Thomson Reuters) Highly Cited Researchers list and as one of TheWorld’s Most Influential Scientific Minds. In 2017, he received the Distinguished ScientistAward (Clinical Domain) from the American College of Cardiology.



13

Eric Adler, MD, FACCProfessor of Medicine

Medical Director, Cardiac TransplantHeart Failure and Transplant Cardiology

UC San DiegoLa Jolla, CA

Eric Adler was born in New York City, New York. He attended NorthwesternUniversity for Undergraduate Studies followed by Boston University where hereceived his MD in 2000. While at Boston University he was awarded the presti-gious Sarnoff Fellowship for Cadiovascular Research. He completed his clinicaltraining in internal medicine at the University of Washington and in CardiovascularDisease at the Mount Sinai School of Medicine. From 2009-2011 he was anAssistant Professor at the Oregon Health and Science University and is currently anAssociate Clinical Professor of Medicine and Medical Director of Cardiac Transplantat the University of California, San Diego

Eric’s clinical interests are in the care of patients with advanced heart failure,mechanical circulatory support and cardiac transplantation. He has a strong inter-est in the use of palliation in heart failure, and has written numerous review articleson the topic.

The focus of his laboratory is the use of pluripotent stem cells for the study andtreatment of cardiovascular disease. In previous work he demonstrated the utilityof these stem cells for the isolation of enriched populations of heart cells. Thesecells can be isolated from both mice and humans, and improve cardiac function inanimal models of myocardial infarction. He also developed novel techniques fortracking these cells once they are injected into the body. More recently he collabo-rated on projects whose focus is the creation of stem cell derived heart cells frompatients with inherited forms of cardiovascular disease. These cells retain essen-tially qualities of the patients from which they were derived. We believe these cellsoffer an unprecedented opportunity to study human heart disease at a molecular level.



14

Inder Anand, MD, PhDProfessor of Medicine

University of Minnesota Medical SchoolVA Medical Centers

Minneapolis, MN and San Diego, CA

Inder S. Anand obtained his undergraduate medical education from India and DPhil (Ph.D.) in cardiovascular physiology from Oxford University, England where hewas a Rhodes scholar. He later trained as a clinical cardiologist in London and wasClinical Senior Lecturer at the National Heart and Lung Institute, London. On returnto India, he joined the Postgraduate Institute of Medical Education and Research(PGI), Chandigarh, established the interventional cardiology program and devel-oped a keen interest in Heart Failure and High-Altitude Medicine and Biology. In thefield of heart failure, he showed that that the stimulus for fluid retention is a threatto the blood pressure, that is common to all congestive states independent of car-diac function. His work on High Altitude Medicine and Physiology lead to the dis-covery of two new syndromes in people living at high altitude; Infantile sub-acutemountain sickness in Tibet, China and Sub-acute adult mountain sickness in Indiansoldiers posted at the Siachen Glacier. He pioneered the use of inhaled nitric oxidein the management of high altitude pulmonary edema in Indian soldiers. He helpedto develop the concept of adaptation in Man and Animals indigenous to high alti-tude by showing that natrives do not respond to hypobaric hypoxia by pulmonaryvasoconstriction because of a lack vascular smooth muscle in the pulmonary arterioles.

In 1991, Dr. Anand moved to the US and accepted the position of Professor ofMedicine, University of Minnesota, and Director of the Heart Failure Program at theVA Medical Center, Minneapolis. He worked on the cellular and subcellular mecha-nisms of heart failure in rodents and showed that early in the natural history ofsevere left ventricular systolic dysfunction, isolated myocyte function is normal,underscoring the importance of ventricular remodeling in the pathogenesis of heartfailure. He has also been very active in designing and conducting clinical trials inheart failure and has been principal investigator in over 80 trials. He has been amember of executive, steering and end-point committees of several internationaltrials. Dr. Anand has authored over 400 peer reviewed scientific publications, over700 abstracts and has over 16,500 citations of his published work with a h-index of65. He is member of the editorial board of several reputed Journals and has wonseveral national and international awards.



15

David Cannom, MD, FACC, FHRSMedical Director of Cardiology, Good Samaritan Hospital

Director of Cardiovascular Trial Development and Engagement,Cedars-Sinai Heart Institute

Clinical Professor of Medicine, UCLA School of MedicineLos Angeles, CA

David S. Cannom, MD, FACC, FACP, is Clinical Professor of Medicine at the UCLASchool of Medicine, Medical Director of Cardiology at the Good Samaritan Hospitalin Los Angeles, California, and electrophysiologist at the Cedars-Sinai HeartInstitute. He is also managing partner of a 10-man cardiology group, Los AngelesCardiology Associates, specializing in coronary and electrophysiology interven-tions.

Dr Cannom received his degree in medicine from the University of MinnesotaSchool of Medicine in Minneapolis, Minnesota, and completed his medical trainingin an internship and residency at Yale-New Haven Hospital in New Haven,Connecticut, and his cardiology training at Stanford University School of Medicinein Stanford, California. Dr. Cannom is Past Governor and President of theCalifornia chapter of the American College of Cardiology. He is also Past Presidentof the North American Society of Pacing and Electrophysiology and Past Presidentof the Heart Rhythm Foundation.

He serves on the editorial boards of Pacing and Clinical Electrophysiology, Journalof Cardiac Electrophysiology, Cardiac Electrophysiology Review, and the Journal ofCardiovascular Pharmacology and Therapeutics. He is the author or coauthor ofapproximately 300 journal articles, book chapters, and abstracts.



16

Maria Rosa Costanzo, MDMedical Director, Heart Failure Research

Advocate Heart InstituteNaperville, IL

Dr. Costanzo received her medical degree summa cum laude from the University ofBologna in Italy. Her postgraduate training included a fellowship in cardiology at LoyolaUniversity Medical Center in Maywood, Illinois. Dr. Costanzo is a Fellow of the AmericanCollege of Cardiology, American Heart Association and European Society of Cardiology. Sheis also a member of the Ordine Dei Medici (The Italian National Medical ProfessionalAssociation).

Dr. Costanzo served as Medical Director of the Loyola University Chicago Heart failure andCardiac Transplant Program from 1988 until 1994. From 1994 until 2001 Dr. Costanzo was theMedical Director of the Heart Failure/Cardiac Transplant Program at Rush University MedicalCenter and was the John H. and Margaret V. Krehbiel Professor of Cardiology at the RushMedical College.

From 1995 until 2000 Dr. Costanzo was the Editor in Chief of the Journal of heart and LungTransplantation.

In 2002 Dr. Costanzo became the Medical Director of the Edward Center for Advanced HeartFailure and Heart Failure Specialist with Midwest Heart Specialists.

In 2002 Dr. Costanzo was appointed by the Secretary of Health and Human Services, theHonorable Tommy Thompson, to serve a four-year term on the National Heart, Lung andBlood Institute Advisory Council.

From 2012 to the present Dr. Costanzo is a member of the American Board of InternalMedicine exam writing committee for the specialty of Advanced Heart Failure andTransplant Cardiology.

Dr. Costanzo has lead several multicenter randomized clinical trials including UNLOAD,AVOID-HF and the Pivotal Trial of phrenic nerve stimulation for central sleep apnea.

Dr. Costanzo has written more than 200 papers, abstracts and articles for journals such asNew England Journal of Medicine, Circulation, Journal of the American College ofCardiology, JACC Heart Failure, Circulation Heart Failure and the European Journal of HeartFailure.

She has presented nationally and internationally on numerous topics related to HeartFailure and Cardiac transplantation.

Dr. Costanzo is also a consultant for several publications including the Journal of theAmerican College of Cardiology, Circulation Research, the New England Journal ofMedicine, the Journal of Cardiac failure, JACC Heart Failure, Circulation Heart Failure, theEuropean Heart Journal, the European Journal of Heart Failure and the InternationalJournal of Cardiology.



17

Barry H. Greenberg, MD, FACCDirector, Advanced Heart Failure Treatment Program

Distinguished Professor of MedicineUniversity of California San Diego Medical Center

La Jolla, CA

Barry H. Greenberg, MD, is Distinguished Professor of Medicine and Director of theAdvanced Heart Failure Treatment Program at the University of California, SanDiego School of Medicine (UCSD). He earned a medical degree from the StateUniversity of New York Upstate Medical University College of Medicine inSyracuse. He completed his internship at George Washington University Hospital inWashington, DC and residency in internal medicine at Yale-New Haven Hospital inNew Haven, Connecticut. Following further research training at the LipidMetabolism Branch of the National Heart, Lung, and Blood Institute in Bethesda,Maryland and the Cardiovascular Research Institute of the University of California,San Francisco School of Medicine (UCSF), he completed a fellowship in cardiologyat UCSF. He then joined the faculty of Oregon Health Sciences University School ofMedicine in Portland. Prior to arriving at his present position at UCSD, he was avisiting professor in residence at both the Royal Postgraduate Medical School inLondon, England and the Laboratoire de Médicine Expérimentale of the Collège deFrance in Paris.

Dr. Greenberg serves on the executive steering and data safety monitoring commit-tees of numerous national and international clinical trials in heart failure. He is afounding member and a past President of the Heart Failure Society of America(HFSA).

Dr. Greenberg has longstanding interests in the basic cellular mechanisms of heartfailure and the development of new forms of therapy. He has published extensivelyin these areas. He is co-editor of Congestive Heart Failure: Pathophysiology,Diagnosis, and Comprehensive Approach to Management, the first comprehensivetext in this field, now in its 3rd edition and editor of Myocardial Remodeling:Mechanisms and Treatment, published in 2006 and Management of Heart Failurepublished in 2010. He is co-author of Contemporary Diagnosis and Management ofCongestive Heart Failure. He is an associate editor of the Journal of the AmericanCollege of Cardiology, and he sits on the editorial boards of several other cardiolo-gy specialty and subspecialty journals. Dr. Greenberg has been recognized by hispeers numerous times over the years as one of the “Best Doctors in America” and“Best Doctors in San Diego.”



18

Yehuda Handelsman, MDMedical Director & Principal Investigator

Metabolic Institute of America Inc.Tarzana, CA

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE is an endocrinologist in pri-vate practice, Medical Director & Principal Investigator of the Metabolic Institute ofAmerica. A Master of the American College of Endocrinology, Fellow AmericanSociety of Preventive Cardiology, of the American College of Physicians and TheNational lipid Association He is Board Member American Association for PreventiveCardiology, Chair of the AACE Lipid & CV Health Disease network. Past president ofthe American College of Endocrinology, AACE & the Pacific Lipid Association, ChairAnnual World Congress on Insulin Resistance, DM & CVD, the Heart in Diabetesand the International Lipid Forum. He published over 110 original research, reviewpapers, editorials and books’ chapters, a recent Book “Clinical Management ofCardiovascular Risk in Diabetes and Obesity”; and is also an author of the AACEDiabetes and Lipids Guidelines



19

Munir S. Janmohamed, MD, FACCMedical Director, Mechanical circulatory Support/Heart Failure Program

Mercy General HospitalMercy Medical Group Cardiology

Sacramento, CA

Dr. Munir Janmohamed is a heart failure cardiologist with Mercy Medical Group inSacramento, CA. He specializes in advanced heart failure, left ventricular assistdevice, critical care medicine, pulmonary hypertension, and digital health. He cur-rently serves as the medical director for the Mercy General Heart Failure andCirculatory Support Program.

Dr. Janmohamed received his Bachelor of Science in biology at University ofCalifornia, Irvine and subsequently received his medical degree from RossUniversity, School of Medicine. He completed his internal medicine residency atLouisiana State University in Lafayette, Louisiana and then pursued a researchheart failure fellowship under the direction of Dr. Uri Elkayam at the University ofSouthern California. His cardiology fellowship was completed at UCSF-Fresnowhere he earned the position of co-chief of fellows and the honor of “Fellow of theYear.” In 2012, he finished his subspecialty training at UCSF in advanced heart fail-ure and pulmonary hypertension.

From 2012-2017, Dr. Janmohamed remained on faculty at UCSF and served as thedirector of program outreach. While at UCSF, Dr. Janmohamed received the presti-gious award, “Redefying Possible,” presented on behalf of a patient to an outstand-ing medical provider. In 2018, Dr. Janmohamed transitioned to his current role withMercy Medical Group and Mercy General Hospital.



20

Alan Maisel, MD, FACCProfessor of Cardiology, UCSD

La Jolla, CA

Dr. Alan S. Maisel graduated from the University of Michigan Medical School,received his internal medicine training at Michael Reese Hospital in Chicago, wherehe was chief resident, and completed a cardiology fellowship at the University ofCalifornia, San Diego.

Dr. Maisel is a Emeritus Professor of Cardiology at the University of California, SanDiego (UCSD). Dr. Maisel is active on the faculty at UCSD where he has wonnumerous teaching awards. He just completed a ten-year stint as Associate Editorof the Journal of the American College Cardiology

Dr. Maisel is considered one of the world’s experts on cardiac biomarkers and hasover 400 scientific publications. He has authored several ground-breaking manu-scripts that have paved the way for development of diagnostic tools for patientswith congestive heart failure. In particular, he was the leading investigator on stud-ies that brought the use of BNP into clinical practice. He has been lead investigatoron seven multicentre biomarker trials.

Dr. Maisel has co-founded three companies, Cardero Therapeutics, Asceptiscope,and Whispering Hearts.

Dr Maisel is also a writer of medical fiction. His first novel, Bedside Manners wasoptioned to Warner Brothers. His second novel, Brain Chicane, is about a youngand idealistic physician working at the premier multiple-organ transplant hospitalin Chicago where he investigates overdose cases that are not totally kosher.

He is the primary care-giver for five children and gave up on sleep five years ago.



21

Mathew S. Maurer, MDArnold and Arlene Goldstein Professor of Cardiology

Professor of MedicineDirector, Clinical Cardiovascular Research Laboratory for the Elderly

Columbia University Irving Medical CenterNew York Presbyterian Hospital

New York, NY

Mathew S. Maurer, MD - Dr. Maurer is a general internist and geriatric cardiologistwith advanced training in heart failure and cardiac transplantation. He is theArnold and Arlene Goldstein Professor of Cardiology at Columbia University,College of Physicians and Surgeons, where directs the Clinical CardiovascularResearch Laboratory for the Elderly (CCRLE) at the Allen Hospital of NewYorkPresbyterian Hospital. Dr. Maurer is a member of the Advanced Cardiac CareCenter at NewYork Presbyterian Hospital – Columbia Campus.

Dr. Maurer received a B.S. in biomedical science as part of the seven-year medicalschool program at CCNY – The Sophie Davis School of Biomedical Education,where he was awarded the Belle Zeller Scholarship. He received his M.D. degreefrom Mount Sinai School of Medicine and graduated Alpha Omega Alpha. He com-pleted training in internal medicine and cardiology at NewYork PresbyterianHospital and was Chief Medical Resident.

Dr. Maurer’s work focuses on evaluating age related changes in cardiovascularphysiology in order to elucidate the mechanism that underlie the higher prevalenceand incidence of cardiovascular disease in older individuals. In much of hisresearch he has focused on the following cardiovascular syndromes – (1) Syncope(fainting), falls and their relationship to disordered blood pressure regulation and(2) Heart failure in the setting of a normal ejection fraction including, (3)Hypertrophic Cardiomyopathy and (4) Cardiac amyloidosis. He has received fund-ing from the National Institute on Aging and National Heart, Lung and BloodInstitute to support his research activities.

He has published over 180 articles including peer reviewed manuscripts, reviewsand book chapters. He was chair of the American College of Cardiology’s GeriatricCardiology Member Section, which is the largest organization dedicated to advanc-ing the care of older adults with cardiovascular disease. He was co-chair of theSteering Committee of the ATTR-ACT trial showing tafamidis was a safe and effec-tive therapy for transthyretin amyloid cardiomyopathy. Throughout his career, hehas promulgated an approach to older adults with cardiovascular disease thatoffers the best of both geriatric and cardiovascular medicine in which a compre-hensive holistic approach to enhance functional capacity and quality of life is at theforefront of emerging techniques to address cardiovascular physiologic derange-ment that disproportionately afflict older adults.



22

Tien M.H. Ng, PharmD, FCCP, BCPS (AQ-C)Associate Professor of Clinical Pharmacy and Medicine

Director, PGY2 Residency in CardiologySchool of Pharmacy & Keck School of Medicine

University of Southern CaliforniaLos Angeles, CA

Tien M.H. Ng, PharmD, FHFSA, FACC, FCCP, BCPS AQ Cardiology is AssociateProfessor of Clinical Pharmacy and Medicine at the University of SouthernCalifornia, and Vice-Chair in the Department of Clinical Pharmacy. He is also thedirector of the PGY2 pharmacy residency in cardiology at the USC School ofPharmacy. Dr. Ng practices as a clinical specialist with the Cardiac Intensive CareUnit team at the LAC + USC Medical Center.

Dr. Ng completed a BS Pharmacy from Dalhousie University in Halifax, Canada, aPharmD from Wayne State University in Detroit and a CardiovascularPharmacotherapy Fellowship from the University of Utah in Salt Lake City. He is aboard certified pharmacotherapy specialist with added qualifications in cardiology.Prior to joining USC, Dr. Ng was on faculty at the University of Nebraska MedicalCenter.

His primary research interests focus on heart failure pathophysiology and pharma-cotherapy. Dr. Ng has published numerous peer-reviewed manuscripts, abstractsand book chapters related to heart failure pharmacotherapy. Dr. Ng has also beenan invited speaker at national pharmacy and cardiology scientific meetings. He hasbeen an active member of ACC, HFSA, ACCP, ASHP, and AHA. Dr. Ng has been con-ferred Fellow of the American College of Clinical Pharmacy, the Heart FailureSociety of America, and the American College of Cardiology. Dr. Ng is a past recip-ient of the HFSA Clinical/Integrative Physiology new investigator award. He wasalso selected to and currently sits on the inaugural Board of PharmaceuticalSpecialties (BPS) Cardiology Specialty Council.



23

Prediman K. Shah, MD, FACCShappell and Webb Family Chair in Clinical CardiologyDirector, Oppenheimer Atherosclerosis Research CenterDirector, Atherosclerosis Prevention and Treatment Center

Cedars-Sinai Heart InstituteProfessor of Medicine and Cardiology,David Geffen School of Medicine, UCLA

Los Angeles, CA

Dr. Shah is the former Chief of Cardiology at Cedars Sinai Heart Institute where hecurrently holds the Shapell and Webb Family Chair in Clinical Cardiology . He isthe founder and Director of Oppenheimer Atherosclerosis Research Center andAtherosclerosis Prevention and Treatment Center as well as Director ofSteven S. Cohen Research Fellowship Program at Cedars Sinai Medical Center. DrShah is also a Professor of Medicine at Cedars Sinai and UCLA. He is the recipientof numerous awards including Gifted Teacher Award and Distinguished ScientistAward: both from the American College of Cardiology and Herrick Award from theAmerican Heart Association, UCLA Dean’s Award of Excellence in teaching andlifetime achievement award from the LA chapter of the AHA. Dr . Shah has madenumerous scientific contributions to the field of acute coronary syndromes, vascu-lar biology and atherosclerosis. His seminal work has included the development ofapo A-I Milano gene based therapy of atherosclerosis and the development of apoB100 related peptide vaccines for atherosclerosis . He has published over 630 sci-entific papers, abstracts, reviews and book chapters and edited three books. He isa member of the editorial boards of JACC, AJC, ATVB , Circulation and serves asthe Guest Editor-in-Chief of JACC. In 2015 he was awarded the Master of AmericanCollege of Cardiology by the ACC at its annual scientific sessions.



24

Nir Uriel, MD, MScLouis Block Professor of Medicine

Director of Heart Failure, Transplant and Mechanical Circulatory SupportSection of Cardiology

The University of Chicago MedicineChicago, IL

Nir Uriel, MD, is a leader in the field of heart failure, mechanical circulatory supportand heart transplantation. He specializes in caring for patients who require mechan-ical circulatory support, including ventricular assist devices (VADs).Dr. Uriel's research focuses on advanced heart failure physiology, heart transplantand mechanical circulatory support. Dr Uriel specialized and reported physiologicalchanges and developed treatment algorithms for patients supported withMechanical Circulatory Support that are being used worldwide. These findings werepublished in the Journal of American College of Cardiology. He has a strong inter-est in high-risk transplant populations, including HIV-positive patients and patientswho have received mediastinal radiation due to tumors or prior transplants.Through his research, Dr. Uriel has improved treatment protocols and patient carefor these high-risk groups.

An accomplished author, Dr. Uriel has published more than 80 original, peer-reviewed articles. In addition, he serves as a reviewer for several scientific journals,including American Journal of Transplantation, Journal of American College ofCardiology and Journal of Heart and Lung Transplantation.



25

table of contents - heart failurelaheartfailure.com/support/heartfailure2019_syllabus.pdf ·...

Documents